Brecanavir

Brecanavir
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C33H41N3O10S2
Molar mass 703.82
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]

On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]

See also

References

  1. Hazen R, Harvey R, Ferris R, et al. (September 2007). "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV". Antimicrob. Agents Chemother. 51 (9): 3147–54. doi:10.1128/AAC.00401-07. PMC 2043237. PMID 17620375.
  2. "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)" (Press release). GlaxoSmithKline. 2006-12-18. Archived from the original on 2008-12-03. Retrieved 2008-06-11.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.